Objective To investigate the complications of gynecological laparoscopies and its related fac-tors. Methods The clinical data of 8700 cases with laparoscopic surgeries from August 2003 to August 2008 were retrospectively analyzed. Results Complications occurred in 259 cases,with a overall complication rate of 2.98%, the serious complication occurred in 37 cases(0.43%), and surgical treatment was needed in 21 cases. The compli-cations included: 129 complications related to puncture and pneumoperitoneum(including subcutaneous emphysema and abdominal wall congestion) ,20 related to bleedings, 17 related to injuries ,26 related to postoperative infections. Conclusion Operative gynecologic laparoscopy-induced complications were associated with operation difficulty, so great attention should be paid. In order to reduce the risks of laparoscopic surgery, indications should be selected cor-rectly,and procedures should be operated carefully.

Objective To explore the effects and mechanisms of ursolic acid on drug-resistant SKOV3/DDP ovarian carcinoma xenografts in nude mice. Methods The models of drug-resistant SKOV3/DDP ovarian carcinoma on athymic mouse were established and randomly divided into four groups with intraperitoneal injection of different drugs: blank control (0. 9%sodium chloride solution ) , cisplatin ( 4 mg·kg-1 ·d-1 ) , ursolic acid low dose ( 30 mg·kg-1 ·d-1 ) , and high dose (60 mg·kg-1·d-1). All drugs were injected at volumes of 10 mL·kg-1 perday for 15 days. The tumor volumes were measured during the process of drug treatment every three days. After 14 days, The tumorigenic rate and tumor inhibition rate were calculated. RT-PCR and Western blotting were performed to detect the expression of Bcl-2 and Bax. Results Anti-tumor rates of cisplatin group , low dose ursolic acid group, and high dose ursolic acid group was 33. 3%, 43. 3%, and 71. 0%, respectively. Bcl-2 expressions were down-regulated, while Bax expressions were up-regulated in all three groups. Conclusion Ursolic acid has some anti-tumor activity on cisplatin-resistant human ovarian cancer SKOV3 /DDP cell in nude mice. It can inhibit tumor growth with dose-effect relationship. The mechanism may be to suppress the expression of anti-apoptotic factor Bcl-2 and to increase the expression of apoptosis-promoting factors Bax.

Objective: To investigate the effect of lncRNA SBF2-AS1 on epithelial-mesenchymal transition (EMT) of cervical cancer HeLa cell via regulating miR-140-5p/VEGFA (vascular endothelial growth factor A) axis. Methods: After cell culture and transfection, the cells were divided into 5 groups: NC group, miR-140-5p mimic group, miR-140-5p mimic+pcDNA-VEGFA group, si-lncRNA SBF2-AS1+pcDNA-VEGFA group and si-lncRNA SBF2-AS1+miR-140-5p mimic group. The expression level of lncRNA SBF2-AS1 in cervical cancer tissues and cell lines was detected by qPCR. The targeted relationship between lncRNA SBF2-AS1, miR-140-5p and VEGFA was confirmed by Dual luciferase reporter gene assay. The expression levels of VEGFA and EMT-related proteins N-cadherin, Vimentin and E-cadherin in HeLa cells were detected by WB. The invasion and migration of HeLa cells were detected by Transwell. Results: lncRNA SBF2-AS1 was highly expressed in cervical cancer tissues and cell lines (P<0.05 or P<0.01). Dual luciferase reporter gene assay confirmed that lncRNASBF2-AS1 targetedly combined with miR-140-5p and VEGFAwas a target gene of miR-140-5p (P< 0.05). Knockdown of lncRNA SBF2-AS1 inhibited invasion and migration as well as EMT of HeLa cells. Further experiment confirmed that lncRNA SBF2-AS1 up-regulated the expression level of VEGFA via miR-140-5p, thereby promoting invasion, migration and EMT of HeLa cells. Conclusion: lncRNASBF2-AS1 promotes EMT of HeLa cells via miR-140-5p/VEGFAaxis.